Table 1.

The study characteristics

Study	Year	Language	Country	Type	Blind	N	Age	Gender (male/female)	Patient characteristics	N of HCQ	N of ST	HCQ treatment	Outcomes	NOS
Chen et al.	2020	English	China	RCT	Double-blinded	62	44.7	33/29	Moderate	31	31	400 mg/day × 5 days	Exacerbated pneumonia on chest CT, progressed illness	-
Chen et al.	2020	Chinese	China	RCT	Open label	30	48.6	21/9	Moderate	15	15	400 mg/day × 5 days	RT-PCR negatively, exacerbated pneumonia on chest CT, and progressed illness	-
Tang et al.	2020	English	China	RCT	Open label	150	46.1	82/68	Moderate	70	80	Load dosage 1200 mg , 800 mg × 2–3 weeks	RT-PCR negatively, progressed illness	-
Magagnoli et al.	2020	English	America	Retro	–	368	68	–	Mild/moderate	210	158	HCQ/HCQ + AZ	Death	7
Gautret et al.	2020	English	France	POS	–	30	52.5	–	Mild	14	16	600 mg/day × 10 days	RT-PCR negatively	7
Barbosa et al.	2020	French	America	Retro	–	38	62.7	–	Moderate	17	21	Load dosage 800 mg, 200–400 mg/day × 3–4 days	Death	6
Mahevas et al.	2020	English	France	POS	–	173	60	–	Pneumonia requiringO2	84	89	600 mg/day × 2 days	Death	7